Full Track-and-Trace Anti-Counterfeiting Not Feasible, Industry Tells FDA
This article was originally published in The Gold Sheet
Executive Summary
The U.S. pharmaceutical industry is telling FDA that a full track-and-trace approach for following drugs through the supply chain is not the best way of dealing with the growing counterfeit problem. In the meantime, industry is devising a number of different approaches.
You may also be interested in...
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Increased Awareness and Internal Programs Have Reduced Cargo Theft
Greater awareness, more collaboration between pharmaceutical manufacturers and beefed up internal security programs have helped reduce pharmaceutical cargo theft.
In Brief
CDER reorganizes for global compliance